UBS Group
ONCY

UBS Group’s Oncolytics Biotech ONCY Stock Holding History

UBS Group’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.9K Buy
50,559
+27,663
+121% +$27.5K ﹤0.01% 7469
2025
Q4 		$20K Hold
22,896
– – ﹤0.01% 7777
2025
Q3 		$32.1K Buy
22,896
+2,100
+10% +$2.35K ﹤0.01% 7851
2025
Q2 		$16.1K Sell
20,796
-102
-0.5% -$54 ﹤0.01% 8584
2025
Q1 		$11.5K Hold
20,898
– – ﹤0.01% 8548
2024
Q4 		$19.1K Sell
20,898
-2,038
-9% -$2.12K ﹤0.01% 7905
2024
Q3 		$20K Buy
22,936
+17,333
+309% +$17K ﹤0.01% 7374
2024
Q2 		$5.55K Buy
5,603
+4,439
+381% +$4.83K ﹤0.01% 7980
2024
Q1 		$1.23K Sell
1,164
-3,535
-75% -$3.95K ﹤0.01% 8185
2023
Q4 		$6.34K Sell
4,699
-2,966
-39% -$4.64K ﹤0.01% 7710
2023
Q3 		$16.7K Sell
7,665
-5,789
-43% -$14.1K ﹤0.01% 6896
2023
Q2 		$35K Buy
13,454
+4,304
+47% +$7.15K ﹤0.01% 6653
2023
Q1 		$11K Buy
9,150
+1,485
+19% +$2.33K ﹤0.01% 7537
2022
Q4 		$12.5K Hold
7,665
– – ﹤0.01% 8264
2022
Q3 		$9K Sell
7,665
-2,558
-25% -$3.13K ﹤0.01% 8590
2022
Q2 		$11K Buy
10,223
+10,058
+6,096% +$12.2K ﹤0.01% 7828
2022
Q1 		$0 Sell
165
-3,140
-95% -$5.27K ﹤0.01% 10709
2021
Q4 		$4K Sell
3,305
-23,485
-88% -$43.4K ﹤0.01% 9537
2021
Q3 		$56K Buy
26,790
+6,101
+29% +$13.8K ﹤0.01% 6250
2021
Q2 		$57K Buy
20,689
+18,577
+880% +$56.9K ﹤0.01% 6314
2021
Q1 		$8K Buy
2,112
+1,948
+1,188% +$5.81K ﹤0.01% 8092
2020
Q4 		$0 Hold
164
– – ﹤0.01% 8636
2020
Q3 		$0 Hold
164
– – ﹤0.01% 8288
2020
Q2 		$0 Sell
164
-580
-78% -$1.09K ﹤0.01% 8245
2020
Q1 		$1K Sell
744
-2,256
-75% -$5.63K ﹤0.01% 7785
2019
Q4 		$14K Buy
3,000
+2,256
+303% +$2.55K ﹤0.01% 7094
2019
Q3 		$0 Hold
744
– – ﹤0.01% 8176
2019
Q2 		$1K Buy
744
+52
+8% +$94 ﹤0.01% 7726
2019
Q1 		$1K Sell
692
-120
-15% -$243 ﹤0.01% 7553
2018
Q4 		$1K Sell
812
-5,241
-87% -$14.2K ﹤0.01% 7907
2018
Q3 		$24K Buy
6,053
+1,762
+41% +$8.19K ﹤0.01% 6700
2018
Q2 		$24K Buy
+4,291
New +$26.4K ﹤0.01% 6572

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group's ONCY Position: Q1 2026 in Review

UBS Group increased its Oncolytics Biotech (ONCY) stake by 121% in Q1 2026, buying an estimated $27.5K and bringing the position to 50,559 shares worth $42.9K. The position accounts for ﹤0.01% of the portfolio, ranked #7469.

UBS Group first reported a position in ONCY in Q2 2018 and has held it in 32 quarters since. The position peaked at $57K in Q2 2021. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • UBS Group held 50,559 shares of Oncolytics Biotech worth $42.9K as of Q1 2026.
  • UBS Group bought 27,663 Oncolytics Biotech shares in Q1 2026, an estimated $27.5K.
  • Oncolytics Biotech made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7469 holding.
  • UBS Group first reported a position in Oncolytics Biotech in Q2 2018 and has held it in 32 quarters since.
  • UBS Group's Oncolytics Biotech position peaked at $57K in Q2 2021.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.